Last reviewed · How we verify
Anhydrovincaleukoblastine (anhydrovinblastine)
Anhydrovincaleukoblastine (generic name: anhydrovinblastine) is a Small molecule drug developed by Roswell Park Cancer Institute. It is currently FDA-approved.
At a glance
| Generic name | anhydrovinblastine |
|---|---|
| Sponsor | Roswell Park Cancer Institute |
| Target | Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma (PHASE1)
- Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anhydrovincaleukoblastine CI brief — competitive landscape report
- Anhydrovincaleukoblastine updates RSS · CI watch RSS
- Roswell Park Cancer Institute portfolio CI
Frequently asked questions about Anhydrovincaleukoblastine
What is Anhydrovincaleukoblastine?
Anhydrovincaleukoblastine (anhydrovinblastine) is a Small molecule drug developed by Roswell Park Cancer Institute.
Who makes Anhydrovincaleukoblastine?
Anhydrovincaleukoblastine is developed and marketed by Roswell Park Cancer Institute (see full Roswell Park Cancer Institute pipeline at /company/roswell-park-cancer-institute).
What is the generic name of Anhydrovincaleukoblastine?
anhydrovinblastine is the generic (nonproprietary) name of Anhydrovincaleukoblastine.
What development phase is Anhydrovincaleukoblastine in?
Anhydrovincaleukoblastine is FDA-approved (marketed).
What does Anhydrovincaleukoblastine target?
Anhydrovincaleukoblastine targets Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1.
Related
- Target: All drugs targeting Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1
- Manufacturer: Roswell Park Cancer Institute — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing